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Abstract
Allogeneic stem cell transplantation (SCT)
from an HLA-haploidentical relative provides a
potentially curative treatment option for hema-
tologic malignancies patients who lack a suit-
ably  HLA-matched  donor.  The  greatest  chal-
lenge  to  performing  HLA-haploidentical  SCT
has been high rates of graft failure and severe
graft-versus-host disease (GVHD). Our group
has been exploring high dose, post-transplan-
tation cyclophosphamide (Cy) as prophylaxis
of  GVHD  after  nonmyeloablative,  HLA-hap-
loidentical  bone  marrow  transplantation,  or
mini-haploBMT.  Among  210  recipients  of
mini-haploBMT, 87% of patients have experi-
enced sustained donor cell engraftment. The
cumulative  incidences  of  grades  II-IV  acute
GVHD and chronic GVHD are 27% and 13%, re-
spectively.  Five-year  cumulative  incidence  of
non-relapse mortality is 18%, relapse is 55%,
and  actuarial  overall  survival  and  event-free
survivals are 35% and 27%, respectively. These
outcomes  suggest  that  mini-haploBMT  with
post-transplantation Cy is associated with ac-
ceptably low toxicities and can provide long-
term survival, if not cure, for many patients
with advanced hematologic malignancies.
Introduction
Post-transplantation Cy as a form
of drug-induced immunologic
tolerance
The idea of giving post-transplantation Cy
came from studies that have shown that im-
munologic tolerance can be induced by the se-
quence of administering an antigen followed
shortly by giving a drug to kill proliferating,
antigen-reactive  T  or  B  cells.  This  phenom-
enon of drug-induced immunological tolerance
is not a new concept. It was initially reported in
1959 when it was shown that giving rabbits 6-
mercaptopurine prevented their ability to pro-
duce  antibodies  against  human  serum  al-
bumin.1
Through  a  progression  of  studies  it  was
found that Cy given one to three days after
antigenic  stimulation  induces  tolerance  to
tumor, skin grafts or other solid organ trans-
plants  in  murine  models.2-4 The  proposed
mechanism has been clonal destruction of al-
loreactive T cells.5 In other words, antigenic
stimulation from the graft causes rapid prolif-
eration of T-cell clones specific to the foreign
antigen. When Cy is given at the height of pro-
liferation, 1-3 days after stimulation, it inhibits
DNA  replication  and  results  in  selective  de-
struction of alloreactive T-cell clones. In vitro
studies have shown this occurs in mature T
cells only.6 Importantly, Cy may not kill those
quiescent T cells that were not activated by ad-
ministration  of  the  antigen.  These  cells  in-
clude pathogen-specific memory T cells, and
this  explains  why  immunity  to  infection  is
spared among patients treated with high dose
Cy outside the context of allogeneic SCT. Thus,
the tolerance induced by post-transplantation
Cy  is  specific  to  the  administered  antigen.
When the antigen administered is allogeneic
cells, post-transplantation Cy induces selective
allodepletion.
Phase II trial of nonmyeloablative,
HLA-haploidentical BMT with
high-dose post-transplantation
cyclophsphamide
Based  upon  encouraging  results  from  a
phase  I/II  trial,7,8 we  recently  completed  a
phase  II  trial  of  nonmyeloablative,  HLA-hap-
loidentical  BMT  with  high-dose,  post-trans-
plantation  Cy  for  patients  with  advanced
hematologic  malignancies.  As  of  September
14th, 2010, 210 consecutive patients received
nonmyeloablative,  HLA-haploidentical  trans-
plantation  with  high-dose,  post-transplanta-
tion cyclophosphamide and had at least one
year of follow-up. Details concerning criteria
for eligibility, HLA typing, outcomes measures,
and  statistical  analysis  have  been  published
previously.8,9
The treatment regimen given to all patients
is  shown  in  Figure  1.  All  patients  were  in-
tended  to  be  treated  as  outpatients.  Condi-
tioning  comprised  cyclophosphamide  14.5
mg/kg/day on days -6 and -5, fludarabine 30
mg/m2/day for five consecutive days starting on
day -6, and 2 Gy total body irradiation given in
a single fraction on day -1. Bone marrow was
harvested from donors and infused into recipi-
ents on day 0. There was no manipulation to
deplete  graft  T-cells.  GVHD  prophylaxis  con-
sisted  of  cyclophosphamide  50  mg/kg  IV,  to-
gether with Mesna, each on days 3 and 4, my-
cophenolate  mofetil  15  mg/kg  po  tid  (max-
imum 3 g/day) from day 5-35, and tacrolimus
from day 5-180. Tacrolimus levels were moni-
tored at least weekly with a desired concentra-
tion from 5-15 ng/ml. Prophylactic antimicro-
bial therapy was started on day -6 and included
norfloxacin,  fluconazole,  appropriate  prophy-
laxis of Pneumocystis carinii pneumonia, and
valacyclovir.
Characteristics of the patients, donors, and
grafts are shown in Table 1. All patients had
poor risk hematologic malignancies that were
judged to be incurable by chemotherapy alone.
Fifty-eight patients had experienced relapse of
their original malignancy after a prior autolo-
gous transplantation procedure, including 22
of the 30 patients with Hodgkin lymphoma and
23 of the 66 patients with non-Hodgkin lym-
phoma. Donors were selected primarily on the
basis of health status, lack of anti-donor HLA
antibodies in the recipient, and ABO and CMV
compatibility, and without regard for the de-
gree of HLA mismatch between donor and re-
cipient.
Engraftment and donor chimerism
Of the 210 patients transplanted, 204 were
evaluable for donor cell engraftment. Twenty-
seven patients (13%) failed to engraft. Nearly
all  patients  with  primary  or  secondary  graft
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failure  experienced  recovery  of  autologous
hematopoiesis.  As  reported  previously,8 the
median time to a neutrophil count of ≥500/ʼL
was 15 days, and the median time to an unsup-
ported  platelet  count  of  ≥20,000/ʼL  was  24
days.
GVHD
Figure  2  shows  that  the  cumulative  inci-
dence of grade 2-4 aGVHD was 27%, grade 3-4
aGVHD was 5% and chronic GVHD was 13%.
This  coincides  with  the  data  previously  re-
ported in the 67 patients, which had shown a
cumulative incidence of grade 2-4 aGVHD of
34%, grade 3-4 aGVHD of 6%.8
Relapse and nonrelapse mortality
The cumulative incidences of relapse and
nonrelapse mortality were 55% and 18%, re-
spectively  (Figure  3).  One  hundred  thirteen
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Figure 1. Treatment schema for nonmyeloablative conditioning regimine in HLA-haploidentical transplantation with post-transplanta-
tion cyclophosphamide. MMF=mycophenolate mofetil; TBI=total body irradiation; Cy=cyclophosphamide; G-CSF=granulocyte colony
stimulating factor.
Figure 2. Cumulative incidence of acute (A) and chronic (B) GVHD after nonmyeloablative haploidentical stem cell transplantation
with post-transplantation cyclophosphamide. n=210
Table 1. Patient, donor, and graft characteristics.
Patient age (median, range) 52 (1-73)
Sex (male/female) 149/61
Diagnoses:
Acute myeloid leukemia 43
Acute lymphocytic leukemia 16
Chronic myeloid leukemia 9
Chronic lymphocytic leukemia 24
Myelodysplastic syndrome 11
Hodgkin lymphoma 30
Non-Hodgkin lymphoma 66
Multiple myeloma 6
Myeloproliferative disorder 5
Donor age (median, range) 42 (14-73)
Parents 35
Siblings or half-siblings 102
Children 73
Graft nucleated cell dose (x 108/kg) 3.7
T cell dose (x 107/kg) 3.7
CD34+cell dose (x 106/kg) 3.7
Median donor/recipient HLA antigen mismatch 4/10*
*Patients and donors were typed at high resolution for HLA-A, -B, -Cw, -DRB1, and -DQB1.[Pediatric Reports 2011; 3(s2):e15] [page 45]
patients have died. The causes of death were
relapse (n=79), infection (n=15), pulmonary
complications  (n=7),  GVHD  (n=5),  other
(n=4), or unknown (n=3).
Overall and event-free survival
Three-year overall survival and event free
survival  are  41%  and  32%  respectively
(Figure 4). Three year overall survival was
50% for patients transplanted for acute lym-
phocytic  leukemia,  45%  for  patients  trans-
planted  for  myelodysplastic  syndrome  or
myeloproliferative disorder, and 35% for pa-
tients  transplanted  for  acute  myeloid
leukemia  (Figure  4B).  Three  year  survival
was 62% for 30 patients with Hodgkin lym-
phoma (22 of whom had undergone prior au-
tologous  SCT),  41%  for  patients  with  non-
Hodgkin  lymphoma,  and  only  22%  for  pa-
tients  with  chronic  lymphocytic  leukemia
(Figure 4C).
Effect of HLA-disparity 
on outcome of HLA-haploidentical
SCT with post-transplantation
cyclophosphamide
Previous studies of T cell-replete, HLA-hap-
loidentical  BMT  after  myeloablative  condi-
tioning have shown that increasing HLA mis-
match between donor and recipient was asso-
ciated with worse survival due to an increased
incidence  of  GVHD  and  NRM,  which  out-
weighed any potential reduction in the inci-
dence of relapse.10-12 Since our regimen incor-
porated  nonmyeloablative  conditioning  and
novel GVHD prophylaxis, we examined the im-
pact of increasing HLA disparity on outcome.9
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Figure 3. Cumulative incidence of relapse and nonrelapse mortality after nonmyeloabla-
tive haploidentical stem cell transplantation with post-transplantation cyclophosphamide.
Figure 4. Actuarial curves of (A) overall survival (OS)
and event-free survival (EFS) in all patients undergoing
nonmyeloablative haploidentical stem cell transplanta-
tion  with  post-transplantation  cyclophosphamide;  (B)
overall  survival  in  patients  with  acute  lymphocytic
leukemia (ALL), acute myelocytic leukemia (AML) or
myelodysplastic syndrome (MDS) or myeloproliferative
disorder (MPD); (C) overall survival in patients with
Hodgkin  lymphoma  (HL),  non-Hodgkin  lymphoma
(NHL) and chronic lymphocytic lymphoma (CLL).[page 46] [Pediatric Reports 2011; 3(s2):e15]
Interestingly, Figure 5 shows a trend to im-
proved event-free survival with increasing HLA
antigen disparity between donor and recipient
(HR = 0.80; 95% confidence interval [CI] =
0.66-0.96; P = .02), with the hazard ratio of 0.8
indicating a 20% reduction in the risk of an
event (death or relapse) for each increment of
HLA  mismatch.  An  HLA-DRB1  antigen  mis-
match in the graft-versus-host direction, and
two or more HLA Class I (HLA-A, -B, and -Cw)
mismatches in either direction were found to
be associated with decreased incidences of re-
lapse without an increased incidence of non-
relapse mortality (data not shown). While an
analysis of the effects of NK cell alloreactivity
on  outcome  is  ongoing,  we  have  previously
found  that  donor-recipient  mismatches  at
genes  for  inhibitory  Killer  Immunoglobulin-
like  Receptors,  or  iKIRs,  or  KIR  haplotypes,
were  associated  with  improved  outcome  of
nonmyeloablative,  HLA-haploidentical  BMT
with post-transplantation cyclophosphamide.13
Discussion
The major advantage of HLA-haploidentical
stem cell transplantation is rapid and near uni-
versal availability of one or more donors, since
all biological parents and children, and 50% of
siblings or half-siblings of a patient are HLA-
haploidentical. Indeed, in our clinical trial the
patients have had an average of four potential
HLA-haploidentical donors for transplantation.
The major disadvantages of this approach have
been  the  consequences  of  intense  bi-direc-
tional  alloreactivity,  i.e.  high  incidences  of
graft failure, severe GVHD, non-relapse mor-
tality, and severe opportunistic infections re-
sulting  from  poor  immune  reconstitution.
High-dose, post-transplantation Cy was devel-
oped  in  mouse  models  of  solid  organ  and
hematopoietic stem cell transplantation as a
method of achieving selective depletion of al-
loreactive T cells in vivo.2,3,14-17The studies de-
scribed here show that high dose, post-trans-
plantation Cy enables HLA-haploidentical stem
cell  transplantation  after  nonmyeloablative
conditioning with acceptably low incidences of
fatal graft rejection, severe GVHD, and non-re-
lapse mortality. The low death rate from oppor-
tunistic infection is testimony to effective clin-
ical immune reconstitution after transplanta-
tion. Interestingly, post-transplantation Cy ap-
pears to nullify the detrimental impact of HLA
mismatching  on  the  outcome  of  allogeneic
SCT for hematologic malignancies.9 The prac-
tical consequence of this finding is that stem
cell donors may be selected without regard to
the  degree  of  donor-recipient  HLA  mis-
matching, and on the basis of biologic or ge-
netic characteristics other than HLA genes. For
example, we are currently conducting a clin-
ical trial of nonmyeloablative allogeneic SCT
and post-transplantation rituximab therapy of
lymphoma, in which donors are selected ac-
cording to Fc(gamma) RIIIa (CD16) genetic
polymorphisms  that  predict  clinical  respon-
siveness  to  rituximab  therapy.18,19 HLA-hap-
loidentical SCT expands access to transplanta-
tion for patients with sickle cell disease, who
have an 18% chance of having a disease-free,
HLA-matched  sibling.20 We  are  currently
testing  whether  post-transplantation  Cy  per-
mits  HLA  mismatching  in  unrelated  donor
transplantation. If so, it may be possible to se-
lect  unrelated  donors  who  are  partially  HLA
mismatched but who harbor a mutation in the
gene for the CCR5 receptor for the human im-
munodeficiency virus. Such individuals are ge-
netically  resistant  to  HIV  infection,  and  as
donors could provide a cure for AIDS through
allogeneic stem cell transplantation.21,22 These
examples  provide  a  taste  of  the  therapeutic
possibilities enabled by a successful crossing
of the HLA barrier. We are currently character-
izing phenotypic and functional immune re-
constitution  after  allogeneic  SCT  with  post-
transplantation Cy, and the mechanisms of Cy-
induced  tolerance  in  the  human.  With  im-
provements  in  our  understanding  of  Cy-in-
duced tolerance,23 and with continued efforts
to improve the safety and efficacy of HLA-hap-
loidentical SCT, we hope to offer this approach
to  cure  increasing  numbers  of  children  and
adults  with  hematologic  malignancies,24 and
extend  this  treatment  to  patients  with  life-
threatening,  non-malignant  hematologic  dis-
orders.
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